Share

In This Section

Home / Blurb / Discussion Detail

FDA Approves Ciltacabtagene Autoleucel for R/R Multiple Myeloma

On Monday, February 28, 2022, the U.S. Food and Drug Administration (FDA) approved ciltacabtagene autoleucel for the treatment of adults with relapsed or refractory (R/R) multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Read Janssen's announcement.

Posted 3/1/2022